Press Releases

Date Title and Summary Additional Formats
Toggle Summary Evoke Pharma Reports Commercial Strategy Progress & Positive Momentum for GIMOTI
Expanded State Medicaid Access for GIMOTI Achieved highest ever monthly GIMOTI prescription fills in May 2024 Promoted former VP of Finance, Mark Kowieski to Chief Financial Officer SOLANA BEACH, Calif. , June 17, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc.
View HTML
Toggle Summary Evoke Pharma to Present Additional GIMOTI Healthcare Utilization Data Focused on Gastroparesis Care Insights in Women at 2024 Digestive Disease Week (DDW) Conference
Evoke commercial booth located at site #737 SOLANA BEACH, Calif. , May 16, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc.   (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ®  (metoclopramide) nasal spray,
View HTML
Toggle Summary Evoke Pharma Reports First Quarter 2024 Financial Results
114% year-over-year increase in net product sales 70% prescriber growth in Q1 2024 compared to Q4 2023 Growing sales metrics reaffirms company’s $14M net revenue guidance for 2024 SOLANA BEACH, Calif. , May 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc.
View HTML
Toggle Summary Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications
Michael Cline, DO., Medical Director Gastroparesis Clinic, Cleveland Clinic to present SOLANA BEACH, Calif. , April 17, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc.  (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an
View HTML
Toggle Summary Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer
SOLANA BEACH, Calif. , March 21, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ®  (metoclopramide) nasal spray, announced that Matthew J.
View HTML
Toggle Summary Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results
Fiscal year 2023 net   product   sales   from   prescriptions totaled approximately $5.2M , a 107% increase from 2022 Company projects $14M in net revenue for 2024 SOLANA BEACH, Calif. , March 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused
View HTML
Toggle Summary Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024
SOLANA BEACH, Calif. , March 07, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti ® (metoclopramide) nasal spray, today announced that the Company is scheduled to
View HTML
Toggle Summary Evoke Pharma Announces Closing of $7.5 Million Public Offering
Potential for Additional $22.5 Million in the Event of Exercise of Common Warrants in Full SOLANA BEACH, Calif. , Feb. 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an
View HTML
Toggle Summary Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million
SOLANA BEACH, Calif. , Feb. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK),  a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ®  (metoclopramide) nasal spray, announced today that it has priced an
View HTML
Toggle Summary Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent
GIMOTI now holds four listed patents with coverage through 2029 SOLANA BEACH, Calif. , Nov. 27, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK),  a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ®
View HTML